SUMMARY
INTRODUCTION
In the central nervous system (CNS), monoamine neurotransmitters, including dopamine, serotonin and norepinephrine, control a variety of physiological, behavioral and endocrine functions (1, 2) . Monoamine-mediated neurotransmission is also critically involved in a number of brain pathological processes such as Parkinson's disease, depression, schizophrenia, and drug addiction (1, 2) . A key step that determines the intensity and duration of monoamine signaling is the transport of released monoamines into brain cells. This process is carried out by cell surface transporters that transport monoamines into presynaptic nerve terminals or neighboring glial cells, where they can be recycled through repackaging into secretory vesicles or degraded by intracellular enzymes (3) (4) (5) .
Uptake of released monoamines into presynaptic neurons is mainly carried out by a family of Na + and Cl -dependent high affinity plasma membrane transporters, which includes the dopamine transporter (DAT), the serotonin transporter (SERT), and the norepinephrine transporter (NET) (3) (4) (5) . These transporters, which share high sequence similarity and belong to the solute carrier 6A (SLC6A) family, are the known targets for many psychostimulants, antidepressants and neurotoxins (3-5).
9). Second, several studies have reported specific dopamine or serotonin uptake in brain regions that do not express SERT or DAT (10) (11) (12) . Finally, recent studies from DAT and SERT knockout mice also provide indirect evidence for the existence of alternative monoamine transporters in the brain (9, 13) . While mechanisms, such as diffusion (14) , heterogenic uptake (15) , or uptake by organic cation transporters (OCTs) (9, 12) , have been proposed to explain these observations, an alternative could be that the brain expresses other monoamine transporters that have not yet been identified at the molecular level.
In this study, we report the cloning and characterization of a novel plasma membrane monoamine transporter, PMAT. We show that PMAT is molecularly distinct from the classic monoamine transporters, abundantly expressed in the human brain and efficiently transports monoamine neurotransmitters. Our findings provide new insights into the complexity and potential compensatory mechanisms of regulating monoamine neurotransmitter levels in the brain.
EXPERIMENTAL PROCEDURES
Cloning of PMAT-Using BLAST search at the National Center for Biotechnology pH 7.4) containing a [ 3 H]-labeled ligand. Uptake was terminated by washing the cells three times with ice-cold PBS buffer, and cells were solubilized and the radioactivity was quantified by liquid scintillation counting. Ascorbic acid (100 µM) and pargyline (10 µM) were present in experiments with monoamines to prevent oxidation. Sodium dependency was assessed in KRH buffer with isotonic replacement of NaCl with Nmethyl-D-glucamine, whereas Cl − dependency was assessed in KRH buffer with chloride salts replaced by corresponding gluconate salts at equivalent molarity. Protein content in each uptake well was measured using a BCA protein assay kit (Pierce, Rockford, IL) and the uptake in each well was normalized to its protein content. The experiments were performed in triplicates and repeated at least three times, and results from the representative experiments are expressed as mean ± S.D. Statistical significance was determined by Student's t-test. Kinetic parameters were determined by nonlinear leastsquares regression fitting as described previously (17) .
Expression in Xenopus laevis
Oocytes-cRNA of PMAT was synthesized and injected into defolliculated oocytes as described previously (17) . Uptake was measured on groups of 8-10 oocytes 2-3 days post-injection at 25°C in transport buffer (100 mM NaCl, 2 mM Semi-quantitative RT-PCR was performed to examine PMAT mRNA expression using the following PMAT specific primers: (5'-CGGGCGTGATGATCTCTCTGAGCCGC ATC-3' and 5'-GGTTGAACACAGCCATGATGAGGATGGGCA-3'). GAPDH primers 
RESULTS
Cloning of PMAT-We initially identified PMAT from the draft human genome database due to its sequence homology to equilibrative nucleoside transporters (ENTs) (18, 19 (Fig. 1a) . A BLAST search revealed that PMAT is not highly homologous to any known proteins and only exhibits low sequence identity (~20%) to mammalian ENTs (SLC29A) (Fig. 1b) . The PMAT gene was previously named human equilibrative nucleoside transporter 4 (hENT4) and assigned to chromosome 7p22.2 (18, 20, 21) . The deduced protein sequence of PMAT is identical to the hENT4 protein predicted from the human genomic DNA (accession number BK000627) (20) . The protein sequence is also identical to that of an hENT4
clone (accession number BC047592) recently isolated from a human brain cDNA library Tissue Distribution-Expression of PMAT in various human tissues was examined by high stringency Northern blotting. A strong, single hybridization signal of 2.9 kilobase (kb) was detected in adult human brain and skeletal muscle (Fig. 2) . Weak hybridization signals were also observed in kidney, heart and liver. In the human brain, strong hybridization signals were found in all regions tested (cerebellum, cerebral cortex, medulla, occipital pole, frontal and temporal lobes, and putamen) and in spinal cord ( and observed by confocal microscopy, the fusion protein was primarily localized to the plasma membrane ( Fig. 3) , suggesting that PMAT is a plasma membrane protein.
Substrate Specificity-To ascertain the functional properties of PMAT, we used MDCK cells to establish a cell line stably expressing PMAT and screened a variety of radiolabeled compounds for uptake activity. Despite its sequence similarity to the equilibrative nucleoside transporters, PMAT does not significantly transport nucleosides and nucleoside analogs such as uridine, cytidine, thymidine, adenosine, inosine, guanosine, and azidothymidine (Fig. 4) . There was also no significant uptake of nucleobases (e.g. uracil, cytosine, adenine, hypoxanthine) or nucleotides (e.g. ATP).
Instead, cells expressing PMAT exhibit a high transport activity for To further define the substrate specificity of PMAT, we performed competition studies GABA and other endogenous compounds exhibited no inhibitory effect (Fig. 6 ).
Prototypical substrates of OCTs (e.g. TEA and guanidine) and the organic anion transporters (e.g. PAH) also did not significantly inhibit PMAT transport activity. These data indicate that PMAT mainly functions as a transporter for biogenic amines.
We next tested whether biogenic amines are indeed substrates for PMAT by directly testing the uptake of radio-labeled compounds. At a substrate concentration of 1 µM and an incubation time of 1 min, PMAT-expressing MDCK cells showed 13-and 20-fold higher serotonin and dopamine uptake than control cells (Fig. 7a) . A 4-to 5-fold increase was also seen for norepinephrine and epinephrine. The increase in acetylcholine uptake is only about 1.4 fold, suggesting that this neurotransmitter is a poor substrate for PMAT ( Fig. 7a) . To confirm that the observed enhanced uptake in MDCK cells was due to heterologous expression of PMAT, we also expressed PMAT in X. laevis oocytes.
Compared to water-injected oocytes, oocytes injected with PMAT cRNA exhibited significantly enhanced uptake of MPP + , serotonin, and dopamine ( Fig. 7b) , further demonstrating that PMAT is a bona fide transporter for monoamines.
Because of the sequence similarity of PMAT to the ENT nucleoside transporters, the possibility that ENTs may as well transport monoamines was investigated. Cells stably transfected with the prototypic ENT transporter, hENT1 (18, 22) , showed no transport activity for MPP + (data not shown), suggesting that there is no significant substrate overlap between PMAT and the ENTs. Together these data demonstrated that PMAT is functionally distinct from nucleoside transporters and has evolved, from the ENT gene family perhaps, to handle biogenic amines.
Transport Kinetics-The transport kinetics of PMAT towards various monoamines was determined from initial rate studies (Fig. 8) . PMAT-mediated monoamine uptake was saturable and the kinetic parameters (K m and V max ) are summarized in Table 1 (23, 24) , the V max values of PMAT-mediated serotonin or dopamine transport are also 2-3 orders higher than the V max values of SERT or DAT. These data suggest that PMAT is a low affinity but high capacity transporter for serotonin and dopamine.
Ion Dependency-To determine the bioenergetics of PMAT-mediated transport, we investigated the effect of Na + and Cl -gradients and membrane potential on PMATmediated MPP + uptake. Replacement of Na + or Cl -in the uptake medium had no effect on uptake activity (Fig. 9a) , suggesting that PMAT-mediated transport does not involve a Na + and Cl -cotransport mechanism. In contrast, depolarization of cells with increased extracellular K + strongly reduced MPP + uptake (Fig. 9b) , indicating that transport is driven by the inside negative membrane potential. To exclude the possibility that the effect of K + on PMAT could be a specific ionic effect, we conducted MPP + uptake experiments in the presence of 10 mM barium with a normal extracellular K + concentration. Barium is an effective potassium channel blocker that can greatly reduce membrane potential in MDCK cells (25) . As shown in Fig. 9c , barium substantially reduced PMAT-mediated MPP + uptake at a low, normal extracellular K + concentration.
These data suggest that the inhibitory effect of high external K + on MPP + uptake was unlikely due to a specific ion effect, but rather related to changes in membrane potential.
Interaction with Transport Inhibitors-To define the pharmacological properties of PMAT, we tested the sensitivity of PMAT to a number of known inhibitors of SERT, DAT, NET, and OCTs (Fig. 10) . The calculated inhibition potencies (K i ) are summarized in Table 2 . Among the inhibitors tested, the cynine dye decynium-22, an (Fig. 11) . This siRNA was then used in A172 cells to test its effect on cellular uptake of serotonin. In parallel with a reduced PMAT mRNA expression level in siRNA treated A172 cells (Fig. 11a) , a consistent decrease in serotonin uptake, ranging from 30-40%, was observed in cells treated with siRNA (Fig. 11b) . These data indicate that the PMAT protein is produced in A172 cells and is functional in this cell line of human glial origin. However, because A172 is a cultured cancer cell line, the results obtained thus may not reflect what happens in vivo.
DISCUSSION
In this study, we identified and characterized a novel human plasma membrane monoamine transporter that is abundantly expressed in the human brain and skeletal muscle. One surprising feature of PMAT is that the transporter is not related to known transporters that interact with monoamine neurotransmitters (i.e. SLC6A and OCTs), but belongs to the equilibrative nucleoside transporter family. Our data clearly demonstrated that unlike the existing ENT members that mainly transport nucleosides and their structural analogs, PMAT specifically transports biogenic amines but does not interact with nucleosides and related compounds. The strong expression of PMAT mRNA in brain and skeletal muscle, tissues that are highly innervated by monoaminergic neurons, is consistent with its functional property.
The characteristics of PMAT, such as Na + -independency, low affinity, and relative insensitivity to inhibitors of DAT, SERT and NET, coincide with earlier findings that described non SLC6A-mediated monoamine uptake activities in the brain (6-9).
Thus, PMAT may be responsible for some of these activities. Our results may also explain monoamine transport activities in brain regions that do not express the SLC6A high affinity transporters or in mice where these transporters are deleted by gene knockout. Additionally, the significant expression of PMAT in skeletal muscle suggests that this transporter may also play a role in sympathetic clearance of norepinephrine.
The functional properties of PMAT seem to complement those of the SLC6A monoamine transporters. While SERT, DAT and NET function as Na + and Cl -dependent high affinity transporters, PMAT-mediated transport is Na + and Cl -independent and is of low affinity and high capacity in nature. It has been suggested that synaptic concentrations of neurotransmitters can transiently reach high concentrations in the millimolar range (26) , where the high affinity transporters would be saturated. Under such conditions, PMAT, which saturates at much higher concentrations, may play an important role in neurotransmitter transport. Additionally, under conditions where the classic SLC6A transporters are inhibited pharmacologically, such as chronic use of antidepressants, PMAT may serve as a backup system for monoamine clearance.
However, it is critical to point out that we have no direct evidence that PMAT participates in monoamine inactivation in brain or skeletal muscle. It is also possible that PMAT functions as a transporter for an unknown substrate that has not been assayed yet.
Further investigations such as extensive substrate screening, detailed brain localization and gene knockout studies are needed to elucidate the in vivo role of PMAT.
Previously, members of the OCT family (SLC22A) have been shown to transport monoamines in a Na + -independent manner (27) . A prominent member is OCT3, also known as the extraneuronal monoamine transporter (EMT). OCT3 transports epinephrine and norepinephrine with low affinities, but does not transport serotonin or dopamine well (28, 29) . OCT3 is mainly expressed in the placenta, heart and liver, and only weakly expressed in the human brain (28, 30) . Nevertheless, OCT3 may contribute to epinephrine and norepinephrine transport in localized brain regions. Taken together, the CNS seems to employ a complex transport system, consisting of both high affinity transporters (DAT, SERT, NET) and low affinity transporters (PMAT and OCT3), to transport monoamines over a wide concentration range.
Brain disorders such as Parkinson's disease, depression and drug addiction affect millions of people worldwide. While the exact causes are unclear, the progression and treatment of these disorders are often associated with alteration of monoamine neurotransmitter levels in the CNS. Thus, the identification of a novel transport NET, norepinephrine transporter; ENT, equilibrative nucleoside transporter; RT, reverse transcriptase; RACE, rapid amplification of cDNA ends; OCT, organic cation transporter. 2 The nucleotide sequence for PMAT cDNA has been deposited in the GenBank database under the Accession Number AY485959. NBMPR is a potent nucleoside transport inhibitor that inhibits endogenous nucleoside uptake activity in MDCK cells. At 10 µM, NBMPR has little inhibitory effect on PMAT. 
